Terms ending in 2042
Every in-force patent on BeiGene, Ltd.'s record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,281,119 | Imidazo[2,1-f][1,2,4]triazin-4-amine Derivatives as TLR7 Agonist In force · High confidence | Beone Medicines I GmbH | In force | High confidence | |
| US 12,667,560 | Co-Administration of Mirdametinib and Lifirafenib for Use in Treating Cancers In force · High confidence | BeiGene, Ltd. | In force | High confidence | |
| US 12,435,104 | Cyclic Dinucleotides as Sting Agonists In force · High confidence | Beone Medicines I GmbH | In force | High confidence | |
| US 12,454,534 | PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF In force · High confidence | Beone Medicines I GmbH | In force | High confidence | |
| US 12,679,844 | Imidazotriazine and Pyrrolopyrimidine Derivatives as Kras G12C Inhibitors In force · High confidence | Beone Medicines I GmbH | In force | High confidence | |
| US 12,459,958 | Tricyclic Compounds as HPK1 Inhibitor and the Use Thereof In force · High confidence | Beone Medicines I GmbH | In force | High confidence | |
| US 12,521,440 | Degradation of Bruton's Tyrosine Kinase (BTK) by Conjugation of BTK Inhibitors with E3 Ligase Ligand and Methods of Use In force · Low confidence | Beone Medicines I GmbH | In force | Low confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by BeiGene, Ltd..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.